| Company* (Country; Symbol) | Company (Country; Symbol) | Type/Product Area | Terms/Details (Date) |
| I. MODIFIED AGREEMENTS | |||
| FEBRUARY | |||
| Cephalon Inc. (CEPH) | ImmuPharma plc (UK; LSE:IMM) | Exercised option for Cephalon to license worldwide rights to lupus drug, Lupuzor | ImmuPharma received $15M when the deal was arranged last fall and now will get a $30M license fee and up to $455M in milestone payments, as well as royalties (2/2) |
| Dyax Corp. (DYAX) | Biogen Idec Inc. (BIIB) | Expanded a phage display drug discovery deal | Dyax will receive $5M up front as well as annual research funding to mine its antibody libraries on behalf of Biogen Idec; Dyax will deliver a minimum of 10 product licenses to Biogen Idec during the course of the three-year deal, and each product could generate up to $85M in milestone payments, as well as eventual royalties for Dyax (2/5) |
| MARCH | |||
| BioRelix Inc.* | Dalton Medicinal Chemistry* (Canada) | Expanded agreement to discover and develop new therapeutics against selected Riboswitch targets | Financial terms were not disclosed (3/23) |
| Med Discovery SA* (Switzerland) | Validapro BioSciences Inc.* | Extended a global partnership with Validapro's subsidiary Laborium Biopharma to encompass the cell culture process development and clinical manufacturing of all molecules under development at Med Discovery | Financial terms were not disclosed (3/13) |
| APRIL | |||
| Cangene Corp. (Canada; TSX:CNJ) | Apotex Group* (Canada) | Revised deal giving Cangene the rights to commercialize its pipeline of recombinant products | The two parties will share the right to market Leucotropin and Accretropin, and Cangene's royalty on Ferriprox (deferiprone) will be phased out over three years (4/16) |
| II. TERMINATED AGREEMENTS | |||
| Endo Pharmaceuticals Holdings Inc. (ENDP) | Durect Corp. (DRRX) | Endo returned U.S. and Canadian rights for the Transdur-Sufentanil pain patch to Durect | The two companies signed a potential $45M deal in 2005, but Durect said the program is no longer a strategic fit for Endo (2/27) |
| XenoPort Inc. (XNPT) | Xanodyne Pharmaceuticals Inc.* | Terminated partnership for the development of XP21510, a preclinical drug for menorrhagia | XenoPort had thus far received $12M up front and $1M out of a potential $129M in milestone payments; rights to XP21510 will return to XenoPort (4/2) |
| Notes: | |||
| * Private companies are indicated with an asterisk. | |||
| Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
| LSE = London Stock Exchange; TSX = Toronto Stock Exchange. | |||
